Our mission is to be a leading genetically-driven biotechnology company developing transformative medicines for human health.
XENON® is a human genetics-based drug development company. Independently and through partnerships with leading global pharmaceutical companies, we identify and validate in humans new targets for drug development and convert that knowledge into innovative and differentiated medicines. Our programs focus on indications of important unmet medical need including orphan disease, pain, anemia, metabolic and cardiovascular disease. Xenon’s pipeline of products spans discovery through to Phase 2 clinical trials.
April 29, 2103 – Xenon to participate in the 12th Annual Needham Healthcare Conference April 30 to May 1 in New York
April 23, 2013 – Teva and Xenon announce FDA orphan drug designation for pain drug XEN402
April 22, 2013 – Xenon Named Company of the year by BIOTECanada
April 17, 2013 – Xenon Exclusively Licenses to Merck Compounds for a Novel Target for Cardiovascular Disease
April 8, 2013 – LifeSciences BC names Xenon as the Life Sciences Company of the Year
February 13, 2013 – Xenon Announces Appointment of EVP, Research and Development
February 5, 2013 – Xenon Receives a Milestone Payment for Marketing Approval of Glybera® in Europe